Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, Moderna, Inc. reported revenue of $1.94B, down 39.9% year over year. Operating margin was -158.1% and net margin -145.2%, on a free-cash-flow margin of -106.2% with capital expenditure at 9.9% of revenue. Every figure is computed directly from MRNA's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $1.94B | -158.1% | -145.2% |
| FY2024 | $3.24B | -121.9% | -110.0% |
| FY2023 | $6.85B | -61.9% | -68.8% |
| FY2022 | $19.26B | 48.9% | 43.4% |
| FY2021 | $18.47B | 72.0% | 66.1% |
How does MRNA compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.